




Figure 1

2/29




Figure 2

3/29




Figure 3

Spleens





Figure 4

4/29

A.



B.




Figure 5

5/29





Figure 6

AGE	BREED	SEX	TUMOR LOCATION	SUBTYPE	GRADE	HER2 SCORE	DOSE	OVERALL SURVIVAL (days)
12.5	American Pit Bull	FS	Proximal humerus	Osteoblastic	II	2	2 x 10 ⁸	738
11.5	Mixbreed	FS	Distal radius	Osteoblastic	I	5	2 x 10 ⁸	267
9	Labrador	MC	Proximal humerus	Fibroblastic	II	7.5	2 x 10 ⁸	1007+
6	Mixbreed	FS	Distal tibia	Osteoblastic	I	4.5	5 x 10 ⁸	973+
7	Rottweiler	MC	Distal ulnar	Osteoblastic	III	2.25	5 x 10 ⁸	955+
4.5	English Bulldog	MC	Proximal humerus	Osteoblastic	I	4	5 x 10 ⁸	346
6	OES	MC	Distal femur	Osteoblastic	II	1.5	1 x 10 ⁹	774+
9	Greyhound	MC	Proximal humerus	Osteoblastic	II	5	1 x 10 ⁹	444
8	Golden Retriever	MC	Distal ulnar	Fibroblastic	I	3	1 x 10 ⁹	518+
2	Labrador	FS	Proximal tibia	Fibroblastic	I	4.5	1 x 10 ⁹	468+
7.5	Cavalier King Charles	FS	Proximal tibia	Osteoblastic	II	7.5	1 x 10 ⁹	469+
6.5	Golden Retriever	FS	Distal radius	Osteoblastic	I	4.5	1 x 10 ⁹	460+
10	Greyhound	MC	Distal femur	Osteoblastic	II	2	1 x 10 ⁹	276
5.5	Labrador	MC	Distal femur	Osteoblastic	I	9	1 x 10 ⁹	342+
9	Golden Retriever	FS	Distal femur	Osteoblastic	I	6	1 x 10 ⁹	366+
6.6	Great Dane	MC	Distal radius	Osteoblastic	II	7.5	3 x 10 ⁹	259
7	Mixbreed	MC	Proximal humerus	Osteoblastic	II	9	3 x 10 ⁹	375+
6.5	Rottweiler	FS	Proximal humerus	Osteoblastic	II	6	3 x 10 ⁹	362+

Figure 7






Figure 9

0.29




Figure 1A

10/29




Figure 11




Figure 12

11/29

Number of Dogs with Treatment Related Adverse Events						
ADXS31-164 dose		2x10 ⁸	5x10 ⁸	1x10 ⁹	3x10 ⁹	Total
Number of dogs recruited		3	3	11	6	23
General Clinical Observations						
Pyrexia (T>103)	Grade 1	2	1	5	5	13
Fatigue	Grade 1	1	0	7	2	10
Nausea	Grade 1	1	2	10	2	15
	Grade 2	1	0	0	0	1
Vomiting	Grade 1	1	2	9	3	15
	Grade 2	2	0	0	3	5
Cardiovascular Abnormalities						
Arrhythmias	Grade 1	0	1	0	0	1
	Grade 2	0	0	0	1	1
Tachycardia	Grade 1	0	0	2	1	3
	Grade 2	0	0	0	1	1
Hypotension		0	0	0	0	0
Hypertension	Grade 1	2	3	8	5	18
Hematological Abnormalities						
Thrombocytopenia	Grade 1	2	2	6	3	13
	Grade 2	0	0	2	1	3
Biochemical Parameters (Analyzed)						
γ-GT	Grade 1	0	2	1	0	3
ALKP	Grade 1	0	1	6	1	8
	Grade 2	0	0	0	1	1
	Grade 3	1	0	0	0	1
ALT	Grade 1	1	1	3	0	5
	Grade 2	0	0	0	1	1
	Grade 3	1	0	0	0	1
AST	Grade 1	1	1	4	2	8
	Grade 2	0	0	2	0	2
	Grade 3	0	0	1	0	1
BUN		0	0	0	0	0
CREA		0	0	0	0	0
Cardiac Troponin I	Grade 1	0	0	1	1	2

Figure 13A




Figure 13B

12/29




Figure 14




Figure 15




Figure 16




Figure 17




Figure 18

16/29




Figure 19




Figure 20

17/29




Figure 21





Figure 22

19/29

All dogs without gross metastatic
disease at the time of first vaccination



Median survival: Control: 316 days
Vaccine: Undefined

Figure 23




Figure 24




Figure 25A




Figure 25B




Figure 25C




Figure 25D




Figure 26




Figure 27B




Figure 27D




Figure 27A




Figure 27C




Figure 28A

Figure 28B

Figure 28C

Dx=diagnosis

FIGURE 28




Figure 29A




Figure 29B




Figure 29C




Figure 29D

29/29




Figure 30A




Figure 30B